AU2003223495A1 - Molecular profiling of disease and therapeutic response using phospho-specific antibodies - Google Patents

Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Info

Publication number
AU2003223495A1
AU2003223495A1 AU2003223495A AU2003223495A AU2003223495A1 AU 2003223495 A1 AU2003223495 A1 AU 2003223495A1 AU 2003223495 A AU2003223495 A AU 2003223495A AU 2003223495 A AU2003223495 A AU 2003223495A AU 2003223495 A1 AU2003223495 A1 AU 2003223495A1
Authority
AU
Australia
Prior art keywords
phospho
disease
specific antibodies
therapeutic response
molecular profiling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223495A
Other versions
AU2003223495A8 (en
Inventor
Katherine Crosby
Bradley Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Signaling Technology Inc
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Publication of AU2003223495A8 publication Critical patent/AU2003223495A8/en
Publication of AU2003223495A1 publication Critical patent/AU2003223495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU2003223495A 2002-04-05 2003-04-07 Molecular profiling of disease and therapeutic response using phospho-specific antibodies Abandoned AU2003223495A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37047302P 2002-04-05 2002-04-05
US60/370,473 2002-04-05
US40852002A 2002-04-07 2002-04-07
US10/408,520 2002-04-07
PCT/US2003/010573 WO2003087761A2 (en) 2002-04-05 2003-04-07 Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Publications (2)

Publication Number Publication Date
AU2003223495A8 AU2003223495A8 (en) 2003-10-27
AU2003223495A1 true AU2003223495A1 (en) 2003-10-27

Family

ID=29254410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223495A Abandoned AU2003223495A1 (en) 2002-04-05 2003-04-07 Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Country Status (2)

Country Link
AU (1) AU2003223495A1 (en)
WO (1) WO2003087761A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
WO2006052249A1 (en) * 2004-11-08 2006-05-18 The Regents Of The University Of California Methods involving the pi3k/akt in gliomas and prostate cancers
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050227266A1 (en) * 2004-02-06 2005-10-13 Ross Douglas T Biomarker:compound correlations in cancer diagnosis and therapy
WO2007086915A2 (en) 2005-05-12 2007-08-02 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
WO2008009004A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008008998A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2011008990A1 (en) 2009-07-15 2011-01-20 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
BRPI0717416A2 (en) 2006-09-21 2013-11-12 Prometheus Lab Inc METHOD FOR PERFORMING A HIGH PRODUCTIVITY COMPLEX IMMUNOASON, AND
US20100112617A1 (en) * 2007-03-20 2010-05-06 Apocell, Inc Evaluating RTK Target Drugs
RU2519647C2 (en) 2007-07-13 2014-06-20 Нестек С.А. Selection of medications for lung cancer therapy by means of antibody-based matrices
CA2923248A1 (en) 2008-02-25 2009-09-03 Nestec S.A. Methods for detecting truncated receptors
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
CN109891237B (en) 2016-10-24 2022-08-23 诺和诺德股份有限公司 Bioassay of insulin preparations

Also Published As

Publication number Publication date
AU2003223495A8 (en) 2003-10-27
WO2003087761A3 (en) 2006-10-05
WO2003087761A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU2003224880A1 (en) Methods of enhancing lysosomal storage disease therapy
EP1511730B8 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
AU2003223495A1 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
IL209010A0 (en) Use of tnfalpha antibodies and another drug
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2003222347A1 (en) Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
AU2002346504A1 (en) Therapeutic protein and treatments
AU2003299581A1 (en) Antibodies against drugs of abuse
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2003289742A1 (en) Stable therapeutic proteins
AU2003294318A1 (en) Therapeutic bioconjugates
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU2003219900A1 (en) Antigene locks and therapeutic uses thereof
AU2002254076A1 (en) Chemokine receptors and disease
AU2002330233A1 (en) Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
AUPR610501A0 (en) Treatment of parasitic disease
AU2003219580A1 (en) Novel therapeutical use of byakangelicin
AU2003298582A1 (en) Therapeutic guanidines
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue
AU2003240052A1 (en) Il-11 derivatives and therapeutic uses thereof
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase